As explained by the National Kidney Foundation, the goal of management of chronic hyperkalemia -- i.e., high levels of potassium in the blood -- is to prevent the development or recurrence of the ...

When you have too much potassium in your blood, it’s called hyperkalemia. There are two types of hyperkalemia: acute and chronic. Acute hyperkalemia is a sudden, severe rise in blood potassium levels.

Understanding predictors of recurrent hyperkalemia may help health care providers provide a more individualized approach to hyperkalemia management. Hyperkalemia recurrence is more likely in patients ...

Hyponatremia at Hemodialysis Initiation Increases Death Risk Nationally standardized treatment algorithms for hyperkalemia should be developed, according to investigators. The following article ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

A recent population-based study assessed the incidence of clinically significant hyperkalemia among adult CKD patients being treated with RAASis and how this affected future treatment. In the study, 9 ...

Hyperkalemia is the medical term for high potassium levels. There are often no symptoms of hyperkalemia, but it can be a sign of kidney disease, dehydration, diabetes complications, and many other ...

Please provide your email address to receive an email when new articles are posted on . Improved potassium levels impacted the physical and/or mental well-being of patients managing hyperkalemia, ...

Please provide your email address to receive an email when new articles are posted on . During study follow-up, 93 patients developed kidney failure with replacement therapy and 134 patients died.

Hyperkalemia is when you have too much potassium in your blood. This may negatively affect the muscles that control your heartbeat and breathing. Especially if left unmanaged, or if you have certain ...

ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd.

As medical professionals, we face an increasingly complex landscape in managing patients with chronic kidney disease (CKD), where hyperkalemia emerges as one of the most significant and recurrent ...